Rationally Repurposing Ruxolitinib (Jakafi®) as a Solid Tumor Therapeutic

Multi-kinase inhibitors can associate with heat shock proteins through their NH2-termini by which they suppress chaperone function

(2016) Laurence Booth et al.   Oncotarget

[Pemetrexed + Sorafenib] lethality is increased by inhibition of ERBB1/2/3-PI3K-NFκB compensatory survival signaling

(2016) Laurence Booth et al.   Oncotarget

Ruxolitinib synergizes with DMF to kill via BIM+BAD-induced mitochondrial dysfunction and via reduced SOD2/TRX expression and ROS

(2016) Mehrad Tavallai et al.   Oncotarget

The afatinib resistance of in vivo generated H1975 lung cancer cell clones is mediated by SRC/ERBB3/c-KIT/c-MET compensatory survival signaling

(2016) Laurence Booth et al.   Oncotarget

Hydroxamic Acid and Benzoic Acid-Based STAT3 Inhibitors Suppress Human Glioma and Breast Cancer Phenotypes In Vitro and In Vivo

(2015) P. Yue et al.   CANCER RESEARCH

Ruxolitinib: A Review of Its Use in Patients with Myelofibrosis

(2015) Greg L. Plosker   DRUGS

Differences in gene expression and alterations in cell cycle of acute myeloid leukemia cell lines after treatment with JAK inhibitors

(2015) Pawel Gunerka et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Inhibition of the autocrine IL-6–JAK2–STAT3–calprotectin axis as targeted therapy for HR−/HER2+breast cancers

(2015) Ruth Rodriguez-Barrueco et al.   GENES & DEVELOPMENT

Recent progress and perspective in JAK inhibitors for rheumatoid arthritis: from bench to bedside

(2015) Yoshiya Tanaka   JOURNAL OF BIOCHEMISTRY

Nexavar/Stivarga and Viagra Interact to Kill Tumor Cells

(2015) Mehrad Tavallai et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Targeting JAK kinase in solid tumors: emerging opportunities and challenges

(2015) M Buchert et al.   ONCOGENE

Resistin and interleukin-6 exhibit racially-disparate expression in breast cancer patients, display molecular association and promote growth and aggressiveness of tumor cells through STAT3 activation

(2015) Sachin K. Deshmukh et al.   Oncotarget

A Chemical Biology Approach to Developing STAT Inhibitors: Molecular Strategies for Accelerating Clinical Translation

(2015) Erik A. Nelson et al.   Oncotarget

Regulation of ERBB3/HER3 signaling in cancer

(2015) Kalpana Mujoo et al.   Oncotarget

Regulation of dimethyl-fumarate toxicity by proteasome inhibitors

(2014) Laurence Booth et al.   CANCER BIOLOGY & THERAPY

Met endosomal signalling: In the right place, at the right time

(2014) Rachel Barrow-McGee et al.   INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY

Sorafenib/Regorafenib and Lapatinib Interact to kill CNS Tumor Cells

(2014) Hossein A. Hamed et al.   JOURNAL OF CELLULAR PHYSIOLOGY

XPO1 (CRM1) Inhibition Represses STAT3 Activation to Drive a Survivin-Dependent Oncogenic Switch in Triple-Negative Breast Cancer

(2014) Y. Cheng et al.   MOLECULAR CANCER THERAPEUTICS

VEGF drives cancer-initiating stem cells through VEGFR-2/Stat3 signaling to upregulate Myc and Sox2

(2014) D Zhao et al.   ONCOGENE

p42/p44 MAPK-mediated Stat3Ser727 phosphorylation is required for progestin-induced full activation of Stat3 and breast cancer growth

(2013) Mercedes Tkach et al.   ENDOCRINE-RELATED CANCER

Tanshinone IIA inhibits breast cancer stem cells growth in vitro and in vivo through attenuation of IL-6/STAT3/NF-kB signaling pathways

(2013) Caiyu Lin et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

STAT signaling in mammary gland differentiation, cell survival and tumorigenesis

(2013) S. Haricharan et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY

Distinct roles of STAT3 and STAT5 in the pathogenesis and targeted therapy of breast cancer

(2013) Sarah R. Walker et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY

Sorafenib Sensitizes Solid Tumors to Apo2L/TRAIL and Apo2L/TRAIL Receptor Agonist Antibodies by the Jak2-Stat3-Mcl1 Axis

(2013) Junaid Abdulghani et al.   PLoS One

Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal

(2013) J. Gao et al.   Science Signaling

Ruxolitinib: The First FDA Approved Therapy for the Treatment of Myelofibrosis

(2012) J. Mascarenhas et al.   CLINICAL CANCER RESEARCH

Simultaneous exposure of transformed cells to SRC family inhibitors and CHK1 inhibitors causes cell death

(2011) Clint Mitchell et al.   CANCER BIOLOGY & THERAPY

Sorafenib Enhances Pemetrexed Cytotoxicity through an Autophagy-Dependent Mechanism in Cancer Cells

(2011) M. D. Bareford et al.   CANCER RESEARCH

Inhibition of MCL-1 in breast cancer cells promotes cell death in vitro and in vivo

(2010) Clint Mitchell et al.   CANCER BIOLOGY & THERAPY

Vorinostat and Sorafenib Increase CD95 Activation in Gastrointestinal Tumor Cells through a Ca2+-De novo Ceramide-PP2A-Reactive Oxygen Species-Dependent Signaling Pathway

(2010) M. A. Park et al.   CANCER RESEARCH

Protein-tyrosine Phosphatase PTPN9 Negatively Regulates ErbB2 and Epidermal Growth Factor Receptor Signaling in Breast Cancer Cells

(2010) Taichang Yuan et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

17-Allylamino-17-Demethoxygeldanamycin and MEK1/2 Inhibitors Kill GI Tumor Cells via Ca2+-Dependent Suppression of GRP78/BiP and Induction of Ceramide and Reactive Oxygen Species

(2010) T. Walker et al.   MOLECULAR CANCER THERAPEUTICS

Vorinostat and Sorafenib Synergistically Kill Tumor Cells via FLIP Suppression and CD95 Activation

(2008) G. Zhang et al.   CLINICAL CANCER RESEARCH